- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01813188
Clinical Trial Based on the Use of Mononuclear Cells From Autologous Bone Marrow in Patients With Pseudoarthrosis
Phase II Clinical Trial of Tissue Engineering Based on the Use of Mononuclear Cells From Autologous Bone Marrow Seeded on Porous Tricalcium Phosphate Biomaterial in Patients With Pseudoarthrosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
An estimated 10% of closed fractures and between 35-45% in cases of open fractures, are at risk of developing a delay in the process of consolidation or a complete failure of it (pseudoarthrosis) depending on location , severity of trauma on bone, soft tissue and vascular structures Some of these cases are refractory to all treatment methods available today, requiring numerous interventions with the potential risk for recurrent infections that they carry. For this reason, its treatment remains a challenge for the orthopedic surgeon.
Recent advances in knowledge of cellular and molecular biology related to the mechanism of bone repair and biomaterials science have been joined in a new discipline called tissue engineering, its implementation in clinical practice is being done so progressive.
Cell therapy based on the use of adult stem cells (MSCs) derived from autologous bone marrow, introduces new applications for the repair of fractures including pseudoarthrosis and avascular bone necrosis.
Its mechanism of action does not focus only on their local action, but also in the release of signaling molecules with autocrine and paracrine action through recruitment and activation of endogenous MSCs to osteoblastic differentiation and bone tissue regeneration.
On the other hand, the seeding of MSCs on biomaterials (natural or synthetic) is more effective, to facilitate adherence, proliferation and extracellular matrix production in the area where implanted.
Today, the investigators can say that there are experimental and clinical evidence supporting the effectiveness of the method.
The investigators have designed a phase II clinical trial to check the feasibility of this approach.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Murcia
-
El Palmar, Murcia, Spain, 30120
- Hospital UniversitarioVirgen de la Arrixaca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pseudarthrosis of tibia established any cause with at least 9 months.
- The pseudarthrosis is not to show signs of healing in the last 3 months.
- The pseudarthrosis subsidiary should not be solely osteosynthesis treatment.
- Age between 18 and 75 years.
- Serology Human Immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) negative.
- Negative pregnancy test in women of childbearing age.
- Patient sufficient guarantees of adherence to protocol.
- Signature written informed consent before a witness
Exclusion Criteria:
- Systemic infection.
- Septic pseudoarthrosis.
- Insufficient skin coverage at the site of nonunion.
- Vascular insufficiency in the affected limb.
- Pathological fracture.
- Concomitant psychiatric or neurological disease.
- Concurrent or prior malignancy treated with chemotherapy over a period of less than 1 year.
- Concomitant severe disease not well controlled.
- Inclusion in other clinical trials.
- Inability to understand the informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ABM seeded onto a porous TCP and DBM
|
cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient. Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM) |
Active Comparator: autologous bone graft
|
autologous bone graft
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time needed to repair the focus of necrosis measured by pain radiography
Time Frame: Baseline and every 14 days up to 180 days
|
Baseline and every 14 days up to 180 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain scale
Time Frame: Baseline and every 14 days up to 180 days
|
Baseline and every 14 days up to 180 days
|
|
Technical success
Time Frame: 6 months
|
Understood as having been able to perform the implant of calcium phosphate matrix loaded with more than 100 million mononuclear cells
|
6 months
|
Morbidity
Time Frame: 6 months
|
Infection of extraction points Pathological fracture of the extraction area Muscle hernia Stress fracture Infection of focus repaired Rupture of the focus fixture repaired Appearance of secondary malignancies
|
6 months
|
Absence of adverse events
Time Frame: 6 months
|
6 months
|
|
physical exploratory
Time Frame: Baseline and every 14 days up to 180 days
|
Baseline and every 14 days up to 180 days
|
|
Analgesia Scale
Time Frame: Baseline and every 14 days up to 180 days
|
Baseline and every 14 days up to 180 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Luis Meseguer Olmo, MD,PhD, Hospital Universitario Virgen de La Arrixaca
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCBO-PS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pseudoarthrosis
-
Central Hospital, Nancy, FranceRecruiting
-
Sebastian FindeisenBonalive Biomaterials LtdRecruitingPseudoarthrosis of BoneGermany
-
Prof. Dr. Cemil Tascıoglu Education and Research...CompletedPseudoarthrosis of Bone | Implant Breakage
-
Universidad Autonoma de Nuevo LeonCompletedPseudoarthrosisMexico
-
Hospices Civils de LyonCompletedPseudoarthrosis of BoneFrance
-
Istituto Ortopedico RizzoliTerminatedPseudoarthrosis of the ClavicleItaly
-
A-Spine Asia Co., Ltd.RecruitingTrauma | Scoliosis | Degenerative Disc Disease | Tumor | Stenosis | Kyphosis | Deformity | Pseudoarthrosis of SpineTaiwan
-
Bezmialem Vakif UniversityCompletedTIBIA PSEUDOARTHROSESTurkey
-
Medicrea, USA Corp.WithdrawnDegenerative Disc Disease | Spinal Stenosis | Spinal Fusion | Kyphoscoliosis | Scoliosis; Adolescence | Pseudoarthrosis of Spine | Kyphoses, Scheuermann